Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action.
Levels of factor VII coagulant activity (FVII:C) and two-chain factor VIIa antigen (FVIIa:Ag) were measured in ten patients before and up to 6 h after receiving a bolus of heparin during percutaneous transluminal coronary angioplasty (PTCA). A significant and sustained post-heparin fall in the level of FVII:C was observed (approximately 30%) without any change in the level of FVIIa:Ag. The level of tissue factor antigen within the circulation remained unchanged. The observed decrease in FVII:C coincided with a significant decrease in triglyceride levels presumably due to lipoprotein and hepatic lipase released by the heparin. These findings appear to demonstrate a lipid (triglyceride) dependence of FVII:C. Thus, heparin may act indirectly as antithrombotic agent by limiting a lipid-dependent activation of the extrinsic pathway of coagulation.
Mukherjee
M
M
Thrombosis Research Institute, Chelsea, London, UK.
Scully
M F
MF
Kakkar
V V
VV
Philippou
H
H
Lane
D A
DA
Jewitt
D
D
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D000941:Antigens / Q000097:blood; D005167:Factor VII / Q000378:metabolism*; D015942:Factor VIIa / Q000276:immunology; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007118:Immunoassay; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000628:therapy*; D013925:Thromboplastin / Q000276:immunology
D000925:Anticoagulants; D000941:Antigens; D005167:Factor VII; D006493:Heparin; D013925:Thromboplastin; D015942:Factor VIIa